A RARE CASE OF MALE BREAST CARCINOMA: A CASE REPORT.
- Department Of General Surgery Santhiram Medical College Nandyal.
10 Downloads
69 Views
Abstract
Significant advances have been made in the diagnosis and treatment of female breast cancer, resulting in a decline in incidence and a global improvement in clinical outcome. The statistics for male breast cancer (MBC) stand in sharp contrast ? over the past several decades, there has been a steady rise in the incidence of this disease, and clinical outcome has improved at a much slower pace. In the current review, the clinicopathologic features of MBC are described in detail. An emphasis is placed on molecular profiling of MBC, which may identify candidate biomarkers and putative targets for pharmacologic intervention. The current role of cytotoxic chemotherapy and endocrine therapy (including tamoxifen, aromatase inhibitors and GnRH analogues) is defined in the context of currently available studies.
Keywords
Article Analytics
References
- Giordano SH. Breast Cancer in Men. New England J Med. 2018;378(24):2311?20
- Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med. 1992;117:771-7
- Kipling M, Ralph JEM, Callanan K. Psychological Impact of Male Breast Disorders: Literature Review and Survey Results. Breast Care. 2014;9:29-33.
- Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer. 1999;85:629-39. 13
- Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer?a meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53:538-49.
How to Cite This Article
Dasari Stephen Naveen and Yeddula.V. Jayaramudu M.S. (2019); A RARE CASE OF MALE BREAST CARCINOMA: A CASE REPORT., Int. J. of Adv. Res., 7 (08), 928-931, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/9581
Corresponding Author
This work is licensed under a Creative Commons Attribution 4.0 International License.





